SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

United Therapeutics Corp. – ‘8-K’ for 5/5/21

On:  Wednesday, 5/5/21, at 6:17am ET   ·   For:  5/5/21   ·   Accession #:  1082554-21-18   ·   File #:  0-26301

Previous ‘8-K’:  ‘8-K’ on / for 4/19/21   ·   Next:  ‘8-K’ on / for 6/3/21   ·   Latest:  ‘8-K’ on / for 6/7/21

Magnifying glass tilted right emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 5/05/21  United Therapeutics Corp.         8-K:2,9     5/05/21   13:587K

Current Report   —   Form 8-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     26K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     83K 
 9: R1          Cover Page Document                                 HTML     46K 
11: XML         IDEA XML File -- Filing Summary                      XML     12K 
 8: XML         XBRL Instance -- uthr-20210505_htm                   XML     21K 
10: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 4: EX-101.CAL  XBRL Calculations -- uthr-20210505_cal               XML      7K 
 5: EX-101.DEF  XBRL Definitions -- uthr-20210505_def                XML      9K 
 6: EX-101.LAB  XBRL Labels -- uthr-20210505_lab                     XML     68K 
 7: EX-101.PRE  XBRL Presentations -- uthr-20210505_pre              XML     33K 
 3: EX-101.SCH  XBRL Schema -- uthr-20210505                         XSD     11K 
12: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    18K 
13: ZIP         XBRL Zipped Folder -- 0001082554-21-000018-xbrl      Zip     26K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX:   C:  C: 
  uthr-20210505  
 i 0001082554 i false00010825542021-05-052021-05-05


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_______________________________________
 
FORM  i 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  i May 5, 2021
 
 i United Therapeutics Corporation
(Exact Name of Registrant as Specified in Charter)
 i Delaware i 000-26301 i 52-1984749
(State or Other
Jurisdiction of
Incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification Number)
 
 i 1040 Spring Street 
 i Silver Spring,
 i MD i 20910
(Address of Principal Executive Offices)(Zip Code)
 
Registrant’s telephone number, including area code:
( i 301)  i 608-9292
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 i     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 i     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 i     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 i     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of exchange on which registered
 i Common Stock, par value $0.01 per share i UTHR i Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  i   
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 



Item 2.02.  Results of Operations and Financial Condition.
 
On May 5, 2021, United Therapeutics Corporation issued a press release setting forth its earnings for the quarter ended March 31, 2021.
 
A copy of the press release is attached hereto as Exhibit 99.1.
 
Item 9.01.  Exhibits
 
This information shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
 
(d)  Exhibits
 
Exhibit No. Description of Exhibit
  
104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.






SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 UNITED THERAPEUTICS CORPORATION
  
 
Dated: May 5, 2021By:/s/ Paul A. Mahon
 Name:Paul A. Mahon
 Title:General Counsel






Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on / For Period end:5/5/2110-Q
3/31/2110-Q
 List all Filings 
Top
Filing Submission 0001082554-21-000018   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2021 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sun., Jun. 13, 5:25:42.2pm ET